Literature DB >> 17958545

Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.

Asad Bashey1, Michael Donohue, Lin Liu, Bridget Medina, Sue Corringham, Anita Ihasz, Ewa Carrier, Januario E Castro, Peter R Holman, Ronghui Xu, Ping Law, Edward D Ball, Thomas A Lane.   

Abstract

BACKGROUND: Interpatient variability in the kinetics of peripheral blood progenitor cell (PBPC) mobilization is commonly seen with conventional chemotherapy-based mobilization regimens. This necessitates the availability of leukapheresis (LP) facilities 7 days a week. STUDY DESIGN AND METHODS: The efficacy of an approach where LP was invariably commenced on Day 11 after intermediate-dose cyclophosphamide followed by sequential administration of granulocyte-macrophage-colony-stimulating factor (CSF) and granulocyte-CSF (Cy/GM/G) was retrospectively analyzed in 225 consecutive, unselected patients undergoing autologous hematopoietic stem cell transplantation for all diagnoses other than acute leukemia at our center. Cy/GM/G was scheduled to avoid weekend LP.
RESULTS: After Cy/GM/G, a CD34+ cell yield of at least 2.0x10(6) per kg was achieved in 90.7 percent of patients. Optimal yield (OY; >or=5x10(6) or 10x10(6) CD34+ cells/kg depending on diagnosis) was achieved in 67.6 percent of patients. Only three patients (1.3%) required LP on Saturday or Sunday. Febrile neutropenia (FN) was encountered in 5.3 percent. PBPC yield was highest on Day 1 of LP (p<0.001). In multivariate analyses, platelet (PLT) count on Day 1 of LP (PLT-D1LP) was positively associated with achievement of OY (p<0.001). PLT-D1LP and diagnosis of myeloma were associated with a shorter time to achieve a CD34+ cell yield of at least 5x10(6) per kg (p<0.001 and p=0.002, respectively).
CONCLUSION: Cy/GM/G with scheduled LP commencement on Day 11 enables optimal CD34+ cell yields in most patients undergoing autologous transplantation, despite a low risk of FN and avoidance of weekend LP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17958545     DOI: 10.1111/j.1537-2995.2007.01440.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.

Authors:  Muneer H Abidi; Nishant Tageja; Lois Ayash; Judith Abrams; Voravit Ratanatharathorn; Zaid Al-Kadhimi; Lawrence Lum; Simon Cronin; Marie Ventimiglia; Joseph Uberti
Journal:  Support Care Cancer       Date:  2011-12-23       Impact factor: 3.603

2.  Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma.

Authors:  M A Gertz; S K Kumar; M Q Lacy; A Dispenzieri; S R Hayman; F K Buadi; D Dingli; D A Gastineau; J L Winters; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2008-11-10       Impact factor: 5.483

3.  Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.

Authors:  Mohamed L Salem; Sabry A El-Naggar; David J Cole
Journal:  Cell Immunol       Date:  2009-12-05       Impact factor: 4.868

4.  The Start-Up of the first Hematopoietic Stem Cell Transplantation Center in the Iraqi Kurdistan: a Capacity-Building Cooperative Project by the Hiwa Cancer Hospital, Sulaymaniyah, and the Italian Agency for Development Cooperation: an Innovative Approach.

Authors:  Ignazio Majolino; Dosti Othman; Attilio Rovelli; Dastan Hassan; Luqman Rasool; Michele Vacca; Nigar Abdalrahman; Chra Abdullah; Zhalla Ahmed; Dlir Ali; Kosar Ali; Chiara Broggi; Cinzia Calabretta; Marta Canesi; Gloria Ciabatti; Claudia Del Fante; Elisabetta De Sapio; Giovanna Dore; Andrea Frigato; Marcela Gabriel; Francesco Ipsevich; Harem Kareem; Dana Karim; Rosa Leone; Tavan Mahmood; Annunziata Manna; Maria Speranza Massei; Andrea Mastria; Dereen Mohammed; Rebar Mohammed; Khoshnaw Najmaddin; Diana Noori; Angelo Ostuni; Angelo Palmas; Marco Possenti; Ali Qadir; Giorgio Real; Rebwar Shrif; Caterina Valdatta; Stefania Vasta; Marta Verna; Mariangela Vittori; Awder Yousif; Francesco Zallio; Alessandro Calisti; Sergio Quattrocchi; Corrado Girmenia
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-04-15       Impact factor: 2.576

5.  Initial Results of Peripheral-Blood Stem-Cell Mobilization, Collection, Cryopreservation, and Engraftment After Autologous Transplantation Confirm That the Capacity-Building Approach Offers Good Chances of Success in Critical Contexts: A Kurdish-Italian Cooperative Project at the Hiwa Cancer Hospital, Sulaymaniyah.

Authors:  Ignazio Majolino; Dereen Mohammed; Dastan Hassan; Francesco Ipsevich; Chra Abdullah; Rebar Mohammed; Angelo Palmas; Marco Possenti; Diana Noori; Dlir Ali; Harem Karem; Salah Salih; Michele Vacca; Claudia Del Fante; Angelo Ostuni; Andrea Frigato; Maria Speranza Massei; Annunziata Manna; Stefania Vasta; Marcela Gabriel; Marta Verna; Attilio Rovelli; Valentino Conter; Kosar Ali; Dosti Othman
Journal:  J Glob Oncol       Date:  2017-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.